Welcome to our dedicated page for Tevogen Bio SEC filings (Ticker: TVGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tevogen Bio Holdings Inc. SEC filings page provides access to the company’s official regulatory disclosures as a U.S. public issuer, including current reports, registration-related documents, and periodic filings referenced in its news releases. These filings offer detailed information on Tevogen’s capital structure, equity programs, governance, and aspects of its financial performance that complement its narrative around capital-efficient execution.
Among the key documents are Form 8-K current reports, where Tevogen has described material events such as a Sales Agreement with a placement agent for at-the-market offerings of common stock under an effective shelf registration statement on Form S-3, restricted stock awards approved by the board of directors, and a personal cash contribution from the founder and Chief Executive Officer to support build-out and first-year operating costs of a new corporate headquarters. These filings also outline terms of equity compensation, vesting conditions, and the mechanics of at-the-market equity issuance.
Investors can also review quarterly reports on Form 10-Q, which the company references in its communications about loss from operations, non-GAAP adjusted loss from operations, and its emphasis on low cash burn and capital efficiency. While the full financial statements and reconciliations are contained in the 10-Q itself, this page serves as an entry point to those documents.
On Stock Titan, Tevogen filings are supplemented with AI-powered summaries that explain the significance of items such as 10-Qs, 10-Ks, and 8-Ks in clear language, helping users understand topics like operating expenses, stock-based compensation, equity sales programs, and insider-related awards. Real-time updates from EDGAR and structured access to forms, including those related to common stock and warrants, make it easier to track how Tevogen’s regulatory disclosures align with its stated strategy in precision T cell therapies and AI-driven drug development.
The SEC has declared Tevogen Bio Holdings' Form S-3 registration statement effective as of June 26, 2025, at 4:30 P.M. This Form S-3 filing (File Number: 333-288218) represents a shelf registration statement that allows the company to offer and sell securities to the public.
Form S-3 is a simplified security registration form used by companies that have met certain reporting requirements and have a minimum public float. This effectiveness notice indicates that:
- Tevogen Bio Holdings can now proceed with its planned securities offering
- The company has satisfied SEC registration requirements
- The registration statement has been reviewed and approved by the SEC
This development is significant for investors as it enables Tevogen Bio Holdings to access the capital markets more efficiently, potentially leading to future securities offerings under this shelf registration.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN, TVGNW) filed Prospectus Supplement No. 3 to incorporate its 8-K dated June 23, 2025. The sole update covers results of the 2025 Annual Meeting. Of 183.9 million shares outstanding, 167.4 million (≈91%) were represented, forming a quorum. Shareholders:
- Elected Class I directors Jeffrey Feike (150.3 m for / 0.65 m against) and Dr. Curtis Patton (150.3 m for / 0.65 m against) for three-year terms.
- Ratified KPMG LLP as independent auditor for fiscal 2025 (167.19 m for / 0.09 m against / 0.08 m abstain).
No other proposals, financial results, or strategic transactions were disclosed. The filing is routine corporate-governance housekeeping and does not alter the company’s risk profile or capital structure.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) filed a Form 8-K dated June 23, 2025 to disclose the final voting results of its 2025 Annual Meeting of Stockholders held on the same date.
Quorum & Share Count: 167,360,586 shares of the 183,893,433 shares outstanding as of the April 30, 2025 record date were present in person or by proxy, establishing a quorum.
Proposal 1 – Election of Class I Directors (term expiring 2028):
- Jeffrey Feike: 150,304,146 FOR; 652,203 AGAINST; 14,742 ABSTAIN; 16,389,495 broker non-votes
- Dr. Curtis Patton: 150,313,660 FOR; 647,811 AGAINST; 9,620 ABSTAIN; 16,389,495 broker non-votes
Both nominees received well over 99% of votes cast in favor and were elected to three-year terms.
Proposal 2 – Ratification of Independent Auditor: Stockholders ratified the appointment of KPMG LLP for the fiscal year ending December 31, 2025 with 167,188,556 FOR; 92,456 AGAINST; 79,574 ABSTAIN; no broker non-votes.
The filing reports no other matters. The results indicate broad shareholder support for the existing board slate and the continued engagement of KPMG. No immediate strategic or financial changes were announced.